Search

everythinglearnresearchcommunity

for

Search:↓

A user is starting a hair loss treatment with a 3-in-1 spray containing finasteride, minoxidil, and tretinoin. They are concerned about whether to continue shaving their head and how to determine if hair follicles are dead.

A 21-year-old male has used 5% topical minoxidil and 1.25mg finasteride for 2 years, improving overall hair but not regrowing temples or crown. He is considering additional treatments like microneedling or dutasteride after a clinic advised against a hair transplant due to existing but damaged follicles.

Applying minoxidil and finasteride to the temples won't cause shedding elsewhere. Shedding occurs due to hair follicles resetting their growth cycle, not the application location.

The user experienced significant hair regrowth using finasteride and dutasteride, with noticeable results after switching to dutasteride. Minoxidil was deemed unnecessary due to the restoration of the hairline and lack of hair follicles in bald spots.

The user experienced significant hair regrowth using topical Minoxidil and oral Finasteride over five months, with darker and thicker hair and new follicles appearing. They are considering waiting 1-2 years before deciding on a hair transplant, as further improvement is expected.

The user is experiencing new hair growth after using oral dutasteride, topical minoxidil, and microneedling, but is concerned about black dots on the hairline, which might be clogged pores or dormant follicles. The user previously used a topical minoxidil/finasteride spray and had good results, despite a shedding phase after switching treatments.

Increasing the finasteride dosage from 1mg every other day to 1mg daily can cause increased shedding, which is normal as hair follicles adjust. Shedding may stabilize in a few weeks to months, and sticking with the new dosage could lead to better long-term results.

The conversation humorously discusses diverting DHT from head to body hair and explores the idea of transplanting body hair to the scalp. It also mentions the potential for treatments to prevent DHT from affecting hair follicles.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

KY-19382, an indirubin derivative, is discussed for its potential to stimulate hair growth and create new hair follicles. The conversation seeks experiences with synthesizing, topically applying, or orally administering KY-19382.